FALANGA, ANNA
 Distribuzione geografica
Continente #
NA - Nord America 5.939
EU - Europa 2.090
AS - Asia 715
SA - Sud America 20
AF - Africa 7
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.779
Nazione #
US - Stati Uniti d'America 5.800
IE - Irlanda 560
SE - Svezia 516
IT - Italia 398
HK - Hong Kong 377
DE - Germania 346
CN - Cina 249
CA - Canada 134
GB - Regno Unito 60
UA - Ucraina 47
VN - Vietnam 42
RU - Federazione Russa 29
AT - Austria 28
FR - Francia 25
FI - Finlandia 19
RO - Romania 16
BR - Brasile 14
SG - Singapore 14
DK - Danimarca 12
ID - Indonesia 12
NL - Olanda 12
IN - India 7
AU - Australia 5
CH - Svizzera 5
MU - Mauritius 5
GR - Grecia 4
IL - Israele 4
JP - Giappone 4
MX - Messico 4
PL - Polonia 4
IR - Iran 3
CL - Cile 2
ES - Italia 2
NZ - Nuova Zelanda 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BG - Bulgaria 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GN - Guinea 1
KR - Corea 1
MA - Marocco 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
Totale 8.779
Città #
Ann Arbor 980
Fairfield 840
Dublin 558
Woodbridge 412
Ashburn 395
Hong Kong 374
Chandler 368
Wilmington 368
Houston 348
Princeton 308
Frankfurt am Main 291
Cambridge 281
New York 271
Seattle 256
Altamura 140
Lawrence 140
Jacksonville 138
Beijing 110
Ottawa 80
San Diego 79
Milan 70
Andover 46
Toronto 46
Falls Church 31
Shanghai 26
Redmond 24
Vienna 23
Dearborn 22
Dong Ket 20
Nanjing 20
Chicago 19
Norwalk 17
London 16
Helsinki 12
Buffalo 11
Jakarta 11
Moscow 11
Singapore 11
Chengdu 10
Florence 10
Wuhan 10
Boardman 9
Fara Gera d'Adda 9
Phoenix 9
Fuzhou 7
Guangzhou 7
Paris 7
Reggio Calabria 7
Rome 7
Shenyang 7
Hefei 6
Kilburn 6
Lachine 6
San Mateo 6
Bonndorf 5
Hounslow 5
Jinan 5
Los Angeles 5
Shenzhen 5
Boulder 4
Bucharest 4
Casoria 4
Cologne 4
Fort Lauderdale 4
Hangzhou 4
Laurel 4
New Bedfont 4
Aiud 3
Bergamo 3
Hebei 3
Huizen 3
Islington 3
Leawood 3
Nanchang 3
New Delhi 3
Oradea 3
Pavia 3
Pisa 3
Taizhou 3
Tel Aviv 3
Trumbull 3
Udine 3
Amsterdam 2
Arnsberg 2
Baotou 2
Bologna 2
Bolzano 2
Brescia 2
Böblingen 2
Carovigno 2
Catania 2
Chivasso 2
Clearwater 2
Conegliano 2
Delhi 2
Deventer 2
Fremont 2
Garges-lès-Gonesse 2
Groningen 2
Hanoi 2
Totale 7.434
Nome #
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 189
Treatment of venous thromboembolism with tinzaparin in oncological patients 186
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 183
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 164
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 139
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 124
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 123
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 121
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 120
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 119
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 116
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 105
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 100
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 99
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 97
Laboratory haemostasis monitoring in COVID-19 96
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 95
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 91
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 87
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 87
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 87
DOACs and “newer” hemophilia therapies in COVID-19: Reply 86
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 84
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 84
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 83
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 82
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 81
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 81
Molecular basis for the relationship between thrombosis and cancer 80
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 79
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 78
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 78
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 77
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 76
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 76
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 76
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 75
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 75
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 74
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 74
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 72
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 72
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 71
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 70
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 68
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 68
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 68
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 68
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 68
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia 68
Procoagulant mechanisms in tumour cells 67
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 67
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 67
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 66
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 65
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 65
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 65
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 65
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 64
Hemostatic biomarkers in occult cancer and cancer risk prediction 64
Several murine metastatizing tumors possess a cysteine proteinase with cancer procoagulant characteristics 62
Acute Promyelocytic Leukemia Coagulopathy. 60
The Italian START-Register on anticoagulation with focus on atrial fibrillation 60
The mechanisms of cancer-associated thrombosis 59
The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence - 15 Years and Counting 59
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 59
Thrombosis in myeloproliferative neoplasms 58
Type and dose of heparin in Covid-19: Reply 58
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 57
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 57
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 56
External validation of the DASH prediction rule: a retrospective cohort study 56
Cancer and venous thromboembolism 55
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 55
Tromboxane synthetase inhibition results in increased platelet sensivity to prostacyclin. Thrombosis and Haemostasis 54
Treatment of thromboembolism in cancer patients 54
Venous thromboembolism in the hematologic malignancies 53
Thrombin generation predicts early recurrence in breast cancer patients 53
Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016 52
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 52
Pharmacological inhibition of thromboxane-synthetase and platelet aggregation: Modulatory role of cyclooxygenase products. 52
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia 52
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 51
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 51
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 51
Risk of Venous Thromboembolism in Surgical Elderly Patients. 50
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 50
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 50
International Forum on GMP-grade human platelet lysate for cell propagation 50
Predicting APL lethal bleeding in the ATRA era 50
Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: reply 50
Clozapine-induced anemia: A case-report 50
Microparticles in tumor progression 48
A validated risk score for venous thromboembolism is predictive of cancer progression and mortality 48
V. Plasmaferesi terapeutica 48
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 48
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 46
Identification of the new HLA-DRB1*14:186 allele in an Italian bone marrow donor 46
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa - Italy, April 23-25, 2010. Preface. 46
Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid 46
Totale 7.487
Categoria #
all - tutte 44.375
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.375


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201922 0 0 0 0 0 0 0 0 0 0 0 22
2019/20201.593 28 21 18 18 15 27 111 618 314 155 179 89
2020/20212.650 269 278 354 163 137 214 287 296 173 162 187 130
2021/20221.551 160 169 178 92 61 74 93 102 68 97 110 347
2022/20232.055 369 575 190 140 96 407 7 91 97 17 41 25
2023/20241.364 27 52 20 18 227 407 262 46 245 20 5 35
Totale 9.455